The ESCaPE-CMD1 trial was an interventional, proof-of-concept study designed to evaluate the ability of Caladrius’s autologous CD34+ cell therapy (CLBS16) to reverse the underlying pathology of CMD, ...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy ...
BASKING RIDGE, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company with ...
Not an acquisition but a “merger of equals.” That’s how Caladrius Biosciences and Cend Therapeutics have described their transformation into the newly christened Lisata Therapeutics. The all-stock ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Caladrius Biosciences, Inc. (NASDAQ: CLBS) and Cend Therapeutics, Inc. is fair to ...
French sugar and ethanol maker Cristal Union reported a 14% fall in annual revenue on Tuesday and warned that higher energy costs and low-duty imports were putting further strain on European ...
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results